Common Stock, $0.0001 par value
- Symbol
- VIR
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Annual Report · 10-K
VIRNASDAQEQUITYCurrent
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN® dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a portfolio of preclinical programs across a range of oncologic malignancies.
Vir Biotechnology, Inc. · 10-K · Filed 2026-02-23